Atorvastatin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Cerebrovascular Accident

Conditions

Cerebrovascular Accident, Hypercholesterolemia

Trial Timeline

Jun 1, 2003 → Feb 1, 2006

NCT ID

NCT00163150

About Atorvastatin

Atorvastatin is a approved stage product being developed by Pfizer for Cerebrovascular Accident. The current trial status is completed. This product is registered under clinical trial identifier NCT00163150. Target conditions include Cerebrovascular Accident, Hypercholesterolemia.

What happened to similar drugs?

4 of 6 similar drugs in Cerebrovascular Accident were approved

Approved (4) Terminated (1) Active (1)

✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved

✅ticagrelor + ASA + Placebo+ASAAstraZenecaApproved

✅Botulinum toxin type A + PlaceboIpsenApproved

✅Atorvastatin 20mgBrain BiotechApproved

🔄donepezil hclEisaiPhase 3

❌AbciximabEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01186289	Pre-clinical	Withdrawn	Oct 1, 2010	Oct 1, 2012	Neurocognitive Dysfunction
NCT00993915	Pre-clinical	Completed	Apr 1, 2010	Dec 1, 2011	Cardiovascular Diseases
NCT00827606	Phase 3	Completed	Mar 1, 2009	Oct 1, 2013	Familial Hypercholesterolemia
NCT00772564	Approved	Completed	Aug 1, 2008	Aug 1, 2010	Myocardial Infarction
NCT00917644	Approved	Completed	Jul 1, 2008	Sep 1, 2008	Hypercholesterolemia
NCT00540293	Approved	Completed	Oct 1, 2007	May 1, 2008	Dyslipidemias
NCT00576576	Pre-clinical	Completed	Jul 1, 2007	Mar 1, 2010	Atherosclerosis
NCT00432354	Phase 2/3	UNKNOWN	Mar 1, 2007	Mar 1, 2009	Systemic Lupus Erythematosus
NCT00172419	Pre-clinical	Completed	Mar 1, 2007	Dec 1, 2008	Hyperlipidemia
NCT00441597	Approved	Completed	Feb 1, 2007	Mar 1, 2009	Ischemia Reperfusion Injury
NCT00343655	Phase 3	Terminated	Jan 1, 2007	Aug 1, 2007	Cardiovascular Diseases
NCT00640744	Approved	UNKNOWN	Feb 1, 2006	Feb 1, 2010	Atherosclerosis
NCT00136942	Phase 3	Completed	Apr 1, 2005	—	Hyperlipidemia
NCT01785615	Phase 1/2	Completed	Nov 1, 2004	May 1, 2013	Metabolic Syndrome
NCT00150371	Phase 3	Completed	Jun 1, 2004	May 1, 2005	Hypercholesterolemia
NCT00644709	Approved	Completed	Sep 1, 2003	Mar 1, 2005	Dyslipidemias
NCT00163150	Approved	Completed	Jun 1, 2003	Feb 1, 2006	Cerebrovascular Accident
NCT00151502	Phase 3	Completed	Nov 1, 2002	Jul 1, 2007	Alzheimer's Disease
NCT00163202	Approved	Completed	Jun 1, 2002	Aug 1, 2005	Coronary Arteriosclerosis
NCT00124397	Approved	Completed	Jul 1, 2001	Dec 1, 2004	Type 2 Diabetes Mellitus

Competing Products

14 competing products in Cerebrovascular Accident

See all competitors

Product	Company	Stage	Hype Score
YM872 (zonampanel)	Astellas Pharma	Phase 2	35
donepezil hcl	Eisai	Phase 3	40
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride	Eisai	Approved	43
ONO-2506	Ono Pharmaceutical	Phase 2/3	30
Abciximab	Eli Lilly	Phase 3	32
atomoxetine + Stimulants	Eli Lilly	Pre-clinical	26
ticagrelor + ASA + Placebo+ASA	AstraZeneca	Approved	43
Valsartan	Novartis	Pre-clinical	18
Rivaroxaban	Bayer	Pre-clinical	19
Darolutamide (BAY1841788) + Enzalutamide	Bayer	Phase 1	26
Botulinum toxin type A + Placebo	Ipsen	Approved	40
Atorvastatin 20mg	Brain Biotech	Approved	40
Autologous bone marrow mononuclear cell transplantation	Brain Biotech	Phase 1	11
Roflumilast Oral Tablet	Brain Biotech	Phase 2	25